Company Overview and News

 
Shaw Helps Businesses Pick Up Speed With SmartWiFi 300 and Business Internet 300

2018-07-10 globenewswire
Businesses across Western Canada can now sync files to the cloud faster, video conference seamlessly and connect more devices
SJR.B SJR WIREX SJRWF SJR.A

2
Shaw Communications' Strong Growth Should Continue

2018-07-10 seekingalpha
The company's investment grade balance sheet will allow it to continue to improve its network quality and speed.
SJR.B SJR SJRWF WMT TU SJR.A

173
Top Stock Reports for Alphabet, JPMorgan & Comcast

2018-06-29 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), JPMorgan (JPM) and Comcast (CMCSA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
SJR.B CMCSA SJR SJRWF SJR.A GOOGL MU KHC GM

4
Former B.C. premier Christy Clark named to Shaw Communications board

2018-06-29 cbc.ca
Former B.C. premier Christy Clark has been named to the board of directors for Shaw Communications.
SJR.B SJR SJRWF SJR.A

177
Shaw Communications (SJR) Beats on Q3 Earnings & Revenues

2018-06-29 zacks
Shaw Communications Inc. (SJR - Free Report) reported third-quarter fiscal 2018 adjusted earnings from continuing operations of 32 cents per share, beating the Zacks Consensus Estimate by a nickel. Including impairment (related to the company’s investment in Corus Entertainment) and restructuring charges of C$297 million, the company reported loss of C$91 million. The company incurred charges of C$13 million related to Total Business Transformation (“TBT”) initiative and Voluntary Departure Program (“VDP”) restructuring programs.
CABO CJREF SJR.B CJR.B AAPL SJR SJRWF PII WMT SJR.A

4
Shaw Communications Inc.'s (SJR) CEO Bradley Shaw on Q3 2018 Results - Earnings Call Transcript

2018-06-28 seekingalpha
Shaw Communications Inc. (NYSE:SJR) Q3 2018 Results Earnings Conference Call June 28, 2018 10:00 AM ET
SJR.B SJR SJRWF SJR.A

4
Shaw Declares Dividend Payable on Preferred Shares

2018-06-28 globenewswire
CALGARY, Alberta , June 28, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (“Shaw”) announced today that its Board of Directors has declared dividends for the three-month period ended September 30, 2018 of $0.17444 per Cumulative Redeemable Rate Reset Class 2 Preferred Share, Series A (“Series A Share”) and $0.20625 per Cumulative Redeemable Floating Rate Class 2 Preferred Share, Series B (“Series B Share”), payable on October 1, 2018 to holders of record at the close of business on September 14, 2018.
SJR.B WIREX SJR SJRWF SJR.A

4
Shaw Declares Monthly Dividends

2018-06-28 globenewswire
CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (“Shaw”) announced today that its Board of Directors has declared monthly dividends of $0.09875 on the Class B Non-Voting Participating Shares and $0.098542 on the Class A Participating Shares, payable on each of September 27, 2018, October 30, 2018 and November 29, 2018 to holders of record at the close of business on September 14, 2018, October 15, 2018 and November 15, 2018, respectively.
SJR.B SJR WIREX SJRWF SJR.A

5
Shaw posts third-quarter loss after $284 million devaluation of its stake in Corus

2018-06-28 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
CJREF SJR.B CJR.B SJR SJRWF TU SJR.A

4
UPDATE 2-Shaw Communications posts surprise loss on Corus investment charge

2018-06-28 reuters
(Reuters) - Canadian telecom company Shaw Communications Inc (SJRb.TO) reported a surprise quarterly loss on Thursday as it booked an impairment charge related to its investment in media company Corus Entertainment Inc (CJRb.TO).
CJREF SJR.B CJR.B SJR SJRWF SJR.A

4
Shaw posts Q3 loss after $284M devaluation of its stake in Corus

2018-06-28 cbc.ca
Shaw Communications Inc. says it lost $91 million in its third quarter, primarily related to a $284-million impairment charge related to its stake in Corus Entertainment Inc.
CJREF SJR.B CJR.B SJR SJRWF SJR.A

4
UPDATE 1-Shaw Communications posts loss on Corus investment charge

2018-06-28 reuters
June 28 (Reuters) - Canadian telecom company Shaw Communications Inc reported a quarterly loss on Thursday, hurt by a C$284 million ($214 million) charge related to its investment in Corus Entertainment Inc.
CJREF SJR.B CJR.B SJR SJRWF SJR.A

4
Shaw Communications reports loss on Corus investment charge

2018-06-28 reuters
June 28 (Reuters) - Canadian telecom company Shaw Communications Inc reported a quarterly loss on Thursday, hurt by a C$284 million ($214 million) charge related to its investment in Corus Entertainment Inc.
CJREF SJR.B CJR.B SJR SJRWF SJR.A

4
Shaw Announces Third Quarter and Year-To-Date Fiscal 2018 Results

2018-06-28 globenewswire
CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (TSX:SJR.B) (TSX:SJR.PR.A) (TSX:SJR.PR.B) (NYSE:SJR) (TSX-V:SJR.A) announces consolidated financial and operating results for the quarter ended May 31, 2018. Revenue from continuing operations for the quarter of $1.30 billion increased 6.9% over the prior year led by Wireless and Business results. Operating income before restructuring costs and amortization1 for the quarter of $547 million increased 7.
CJREF SJR.B CJR.B SJR DTK WIREX SJRWF SJR.A

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 82028K101